Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET
Company Participants
Diane Weiser - Senior Vice President, Corporate Affairs
Robert Blum - President & Chief Executive Officer
Fady Malik - Executive Vice President, R&D
Andrew Callos - Executive Vice President & Chief Commercial Officer
Stuart Kupfer - Senior Vice President & Chief Medical Officer
Sung Lee - Executive Vice President & Chief Financial Officer
Conference Call Participants
Tess Romero - JPMorgan
Salim Syed - Mizuho
Cameron Bozdog - BofA
Sean McCutcheon - Raymond James
Paul Choi - Goldman Sachs
Jason Butler - Citizens JMP
Srikripa Devarakonda - Truist Securities
Mayank Mamtani - B. Riley Securities
Yasmeen Rahimi - Piper Sandler
Rohan Mathur - Oppenheimer
Operator
Good afternoon, and welcome to Cytokinetics' Third Quarter 2024 Conference Call. At this time, I would like to inform you that this call is being recorded. And all participants are in a listen-only mode. At the company's request, we will open the call to questions after the presentation [Operator Instructions]
I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Affairs. Please go ahead.
Diane Weiser
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments; Fady Malik, EVP of R&D, will provide updates related to clinical development program for aficamten; Andrew Callos, EVP and Chief Commercial Officer will address commercial readiness activities for aficamten; Stuart Kupfer, SVP and Chief Medical Officer, will provide updates regarding omecamtiv mecarbil, CK-586 and our earlier stage development pipeline; Sung Lee, EVP and Chief Financial Officer, will provide a financial overview of the third quarter. And finally, Robert will review our corporate development strategies and review expected upcoming milestones.
Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements.
Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report regarding our third quarter 2024 financial results filed on Form 8-K that was furnished to the SEC today. We undertake no obligation to update any forward-looking statements after this call.